A Phase I, Dose Escalation Study of MLN1117 in Subjects With Advanced Solid Malignancies Followed by Expansion in Subjects With Measurable Disease
Phase of Trial: Phase I
Latest Information Update: 10 May 2017
At a glance
- Drugs Serabelisib (Primary)
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Takeda Oncology
- 10 May 2017 Results (n=71) published in the Clinical cancer research: an official journal of the American Association for Cancer Research
- 04 Nov 2016 Status changed from active, no longer recruiting to completed.
- 17 Dec 2015 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.